Teva-Ivax Merger Puts Spotlight On Authorized Generics
Teva Pharmaceutical Industries Ltd.'s $7.4 billion purchase of Ivax Corp. will once again propel the Israeli drug maker past Novartis as a leader in the $58-billion worldwide market for generic drugs....To view the full article, register now.
Already a subscriber? Click here to view full article